Pexidartinib is an inhibitor of proto-oncogene receptor tyrosine kinase (KIT), colony-stimulating factor-1 receptor (CSF1R) and FMS-like tyrosine kinase 3 (FLT3), and was shown to decrease the load of intratumoral TAMs and increase the proportions of CD4+ and CD8+ T cells, thus contributing to the tumor regression [114]. This evidence concerns the gene CD4 and neoplasm.